Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iSpecimen Inc. (ISPC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. iSpecimen’s filings offer detailed information about its online marketplace for human biospecimens, its capital structure, financing activities, governance, and interactions with The Nasdaq Capital Market. Stock Titan enhances these documents with AI-powered summaries designed to explain the key points of each filing in clear language.
For investors and analysts reviewing annual reports on Form 10-K and quarterly reports on Form 10-Q, iSpecimen’s disclosures describe its mission to accelerate life science research through a global biospecimen marketplace, its technology platform, and its classification as an emerging growth company and smaller reporting company. These periodic reports, when available, are central sources for understanding the company’s business model, risk factors, and operating environment.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings include a November 21, 2025 report describing a Nasdaq notice that the company’s closing bid price had fallen below the $1.00 minimum required under Listing Rule 5550(a)(2), along with the timeframe provided to regain compliance. Other 8-Ks detail leadership changes, such as the appointment of a new Chief Executive Officer and the addition of an independent director, and report the results of a special meeting of stockholders where proposals related to a reverse stock split, an increase in authorized shares, private financing approvals, amendments to convertible securities, and an equity line of credit were approved.
Proxy statements on Schedule 14A (DEF 14A) shed light on corporate governance, director elections, stock incentive plans, and the agenda for annual and special meetings. The 2025 special meeting proxy statement outlines proposals to adjust the company’s capital structure and financing flexibility, while the 2025 annual meeting proxy statement covers director elections, auditor ratification, and a new stock incentive plan.
iSpecimen’s registration statements on Form S-1 and S-1/A describe offerings of common stock and pre-funded warrants, the use of proceeds, and detailed background on the company’s marketplace model. These filings also incorporate discussion of the company’s corporate treasury plan related to the Solana blockchain ecosystem and associated risk factors, as noted in the explanatory notes to recent amendments.
On Stock Titan, users can review these ISPC filings as they are updated in real time from EDGAR, while AI-generated overviews highlight important elements such as capital-raising terms, listing compliance matters, governance proposals, and structural changes to outstanding securities. This combination of source documents and AI explanations helps readers navigate complex forms, from 10-Ks and 10-Qs to 8-Ks, S-1 registration statements, and proxy materials, and track how iSpecimen manages its biospecimen marketplace business within the public-company regulatory framework.
iSpecimen Inc. operates a technology-driven marketplace that connects life science researchers with human biospecimens and associated data sourced from a global healthcare provider network. The iSpecimen Marketplace aggregates de-identified data from electronic health systems, enabling researchers to search, select, and procure specimens and custom collections through an integrated workflow from inquiry to invoice.
As of December 31, 2025, the platform incorporated approximately 19 million patient records, 105 million clinical specimen records, and 1.4 million banked specimen records, and had delivered over 218,000 specimens across more than 3,500 projects. The company is migrating from a legacy architecture to a cloud-native system built on its SalesStack solution to improve scalability, security, and workflow unification.
Financially, iSpecimen reported net losses of $10.5 million in 2025 and $12.5 million in 2024, with an accumulated deficit of $82.4 million and an explanatory going-concern paragraph in its audited financial statements. The workforce shrank from 24 employees at the end of 2024 to seven at the end of 2025. The company also disclosed a material weakness in internal control over financial reporting related to sales tax processes and is implementing remediation measures. Revenue and cost of revenue are concentrated among a small number of customers and suppliers, and the business depends heavily on expanding its supply network, data access, and marketplace capabilities in a highly regulated environment.
iSpecimen Inc. has been unable to complete its 2025 Annual Meeting of Stockholders because not enough shareholders have participated to reach a quorum. The meeting, originally convened on December 31, 2025 and reconvened on January 23, 2026, February 13, 2026, and March 13, 2026, was adjourned each time for this reason.
The company now plans to reconvene the Annual Meeting on April 10, 2026 at 9:00 a.m. Eastern Time. The record date remains November 3, 2025, and the proposals to be voted on are unchanged from those described in the definitive proxy statement filed on November 21, 2025.
iSpecimen Inc. reported that Siyun Yang resigned from its Board of Directors effective February 17, 2026. The company stated that her resignation was not due to any disagreement regarding operations, policies, or practices.
Ms. Yang had served as an independent director since February 2025 and sat on both the Audit Committee and the Nominating and Corporate Governance Committee. iSpecimen thanked her for her service and expressed well wishes for her future endeavors.
iSpecimen Inc. reported that its 2025 Annual Meeting of Stockholders, originally convened on December 31, 2025, has been repeatedly adjourned because not enough shares were represented to reach a quorum. The meeting was reconvened on January 23, 2026 and February 13, 2026, but a quorum was still not present.
The company now plans to reconvene the Annual Meeting on March 13, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of November 3, 2025 remain entitled to vote, and the proposals to be considered are unchanged from those described in the November 21, 2025 proxy statement.
iSpecimen Inc. filed a current report to share two operational updates. The company has completed Milestone 2 of its SalesStack digital transformation program, delivering a fully integrated, live production marketplace that connects customer requests with supplier inventories and supports core workflows like order processing and user management.
The new marketplace is live at mp.ispecimen.com and is designed to streamline operations, reduce costs, and support future growth through AI-assisted matching and legacy system sunset. Separately, iSpecimen highlighted recent performance of its site network, including rapidly procuring 500 influenza swab samples in a few weeks and consistently supplying cerebrospinal fluid for ongoing customer studies, alongside strong customer feedback on specimen quality and documentation.
iSpecimen Inc. is registering up to 101,000,000 shares of common stock for resale by existing investors. These shares are issuable upon conversion of Series C Convertible Non-Voting Preferred Stock that was sold in a December 2025 private placement for approximately $5.5 million of gross proceeds.
The company will not receive any proceeds from sales of these shares by the selling stockholders. After full conversion and completion of this offering, iSpecimen states there would be 110,771,046 shares of common stock outstanding. Its stock trades on the Nasdaq Capital Market under the symbol ISPC, and the company recently regained compliance with Nasdaq’s stockholders’ equity rules but remains below the $1.00 minimum bid requirement.
iSpecimen Inc. is experiencing delays in completing its 2025 Annual Meeting of Stockholders due to repeated failure to reach a quorum. The company first convened the meeting on December 31, 2025, but adjourned it when too few shares were represented to conduct official business.
The meeting was reconvened on January 23, 2026 and again adjourned for the same quorum issue to give stockholders more time to vote on the proposals outlined in the definitive proxy statement filed on November 21, 2025. iSpecimen now intends to reconvene the Annual Meeting on February 13, 2026, keeping the record date of November 3, 2025 unchanged, meaning only holders of record on that date are entitled to vote.
iSpecimen Inc. is registering 101,000,000 shares of common stock for resale by investors who hold Series C Convertible Non-Voting Preferred Stock issued in a December 2025 private placement. These “Conversion Shares” will become issuable upon conversion of 6,875 Series C preferred shares and any related anti-dilution adjustments under the Certificate of Designation. After the offering, iSpecimen would have 110,771,046 common shares outstanding if all Conversion Shares are issued.
The company will not receive proceeds from sales by the selling stockholders. It already raised approximately $5.5 million in gross proceeds in the December 2025 private placement, paying a 4% cash commission to E.F. Hutton & Co. and using $2,000,000 for marketing and investor relations services from IR Agency LLC, with the remainder for working capital and general corporate purposes. iSpecimen notes that large resales under this registration could put downward pressure on its share price.
iSpecimen operates an online biospecimen marketplace connecting healthcare providers with life science researchers. The company recently regained compliance with Nasdaq’s stockholders’ equity rules but remains out of compliance with the $1.00 minimum bid price requirement and has until May 18, 2026 to cure this deficiency. Its common stock trades on the Nasdaq Capital Market under the symbol “ISPC”.